Today's Fun Alert: (NYSE:NNVC)
Rise and shine traders!
If you missed the report last night,
(NYSE:NNVC) is in the spotlight with a chart that's easy on the eyes.
Just a few weeks ago the stock was at its 52 week high!!!
NNVC seems to have pulled back which could create an interesting opportunity..
Can we see this rally back to the mid $3.00's??
Keep watching (NYSE:NNVC) as all the fun and action unfolds into the open!!! 
NNVC's NV-387 (if found to be effective in human clinical studies) could catapult the company into the spotlight!
Greetings Investors,
With this alert, we take you to the exciting world of biotech and to a company that could soon revolutionize how we treat viruses the way antibiotics treat bacteria!
Hurry and add NanoViricides, Inc. (NYSE: NNVC) to your radar!
NNVC is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Additionally, nanoviricides mimick the host-side features that the viruses continue to require in spite of mutations, and therefore the viruses would be highly unlikely to escape the nanvoricide drugs.
Bullish ratings are piling up…
NNVC is currently trading a little over $3 and carries a "STRONG BUY" rating at BarChart.com.
The stock also has other bullish ratings including a "STRONG BUY" at Investing.com, a "STAY LONG" rating at AmericanBulls.com, and a "VERY BULLISH" rating at StockTA.com.
NNVC additionally has a $6.50 price target which can be seen HERE.
Why is there so much positive sentiment around this emerging biotech company right now?
Perhaps it's because NNVC is developing a first-in-class, broad-spectrum antiviral agent that is intended to revolutionize the treatment of viral infections which includes Covid, RSV, influenza, and others!
Let's dig into why this is important…
No matter how much a virus changes in the field, it uses the same "landing sites" in the host body to gain access to cells, attach to, and then fuse into the cells, causing an infection. A drug using the same landing sites and acting as a "decoy" would remain effective against the virus even as the virus changes, because the host side does not change.
NNVC has this kind of an answer and it's called NV-387!
NV-387 is designed to employ such advanced "host-mimetic" technology, built into the nanoviricide™ nanomedicine that is further designed to "look like a cell" to the virus. In contrast, vaccines, antibodies, and small chemical drugs all lose their effectiveness as the virus changes in the field. The virus is constantly changing due to various natural mechanisms such as mutations, recombinations, and/or re-assortments that are native to the virus lifecycle.
Over 90% of human pathogenic viruses are known to use one or more "landing sites" that are in the Sulfated Proteoglycans ("SPG") family. A successful host-mimetic nanoviricide drug using SPG as the key feature to attract viruses could theoretically be able to attack most if not all such viruses.
NV-387 is designed to mimic SPG and attack the virus as a cell-mimicking decoy.
The company has accumulated substantial evidence that in lethal viral infection animal studies and NV-387 demonstrated strong antiviral activity against a range of different virus families, exceeding or matching the activity of known approved drug agents! NV-387 was substantially superior to remdesivir in coronavirus infections, using a model for SARS-CoV-2 (COVID) virus.
The Company has already developed an injectable formulation of NV-387, namely NV-387 Solution for Injection, Infusion, and Inhalation.
An injection of NV-387 would be useful for moderate to severe illness, especially because of the sustained blood profile that requires infrequent dosing.
An infusion would be suitable for severely ill hospitalized patients.
Importantly, this NV-387 Solution can be readily delivered directly into the lungs of a patient using a simple handheld nebulizer over a period of a few minutes. Such delivery can enable direct attack on the virus where such attack is most needed in the cases of severe lung infection.
The utility of NV-387 is extremely broad, reminiscent of the utility of antibiotics!
NNVC has found that NV-387 could cure lethal lung infection in RSV infected animals even with an oral dose. There is no approved drug for RSV treatment other than the toxic, last resort drug ribavirin, which was not very effective in this lethal study compared to NV-387.
Recently the company had big news revealing that the strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV infection animal model. The animals in only the NV-387 treated group survived completely, as previously reported. In contrast, lethally infected animals in the Ribavirin oral treatment group showed progressive lung pathology, demonstrating progressive inflammation in the lung tissue which resulted in moderate levels of inflammation as well as infected cells in the inflammatory infiltrate on day 10, increasing to severely infected lungs with alveolitis and severe pneumonia by day 13. All animals in the ribavirin-treated RSV infected group died by 14 days.
No approved treatment currently exists for RSV other than ribavirin. This means a safe and effective treatment remains an unmet medical need and offers this company an incredible market opportunity.
The company has also found that NV-387 IV administration as well as PO (Oral) administration was substantially superior to each of the approved drugs Tamiflu, Rapivab and Xofluza in an Influenza A/H3N2 lethal lung infection model.
Additionally. NNVC has discovered that NV-387 is expected to possess similar strong antiviral activity against Influenza A/H5N1 "Bird Flu" viruses as well. This belief is based on the putative mechanism of NV-387. NV-387 is a host-mimetic, direct-acting antiviral designed as a decoy, to look like a cell decorated with sulfated proteoglycans, to which over 90% of human pathogenic viruses including H5N1 are known to bind.
The fight continues against Covid….
NV-387 has strong antiviral activity against all tested coronaviruses, including SARS-CoV-2 pseudovirions. NV-387 was substantially more effective than remdesivir in a lethal coronavirus infection animal study. We believe that NV-387 has a strong potential for the treatment of COVID as well as "Long COVID".
COVID continues to cause substantially more fatalities annually than Influenza viruses. Long COVID has substantial personal as well as societal costs. The available drug, Paxlovid (Pfizer) has significant limitations for patient suitability. Thus a new drug against COVID and Long COVID is sorely needed!
In Summary…
The success of penicillin led to an explosion in the development of antibacterials. But what about fighting viruses?
NanoViricides, Inc. (NYSE: NNVC) is on a solid footing to revolutionize the treatment of antiviral infections with game-changing antiviral nanomedicines. These drugs could be as revolutionary as antibiotics and do not rely on immune systems making them great for seniors and children!
The company's lead drug candidate NV-387 is aimed to treat RSV, Covid-19, Long Covid, Influenza, Bird Flu H5N1, and other respiratory viral infections.
You may see why BULLish ratings are accumulating for NNVC with the exciting antiviral medicine the company is working on.
Learn more about how NNVC's NV-387 may become the next revolutionary antiviral medicine and put the stock high on your radar!
